Piper Jaffray initiates its coverage on Henry Schein HSIC with a Neutral rating and a price target of $81.
Piper Jaffray notes, "HSIC is a leading distributor of dental, veterinarian, and medical office supplies. We believe HSIC is fairly valued, and given the company's international exposure and meaningful concentration to Europe (28% of revenues), FX headwinds could lead to lower than expected Q2 revenues. Additionally, IDEXX will move one of its three exclusive vet distributors to non-exclusive status in 2013, which would lower gross margins from 15% to 5% and potentially lead to lower revenues. Until these issues are resolved, we believe HSIC could be range-bound. Our $81 PT is based on 17x our FY13E EPS."
HSIC closed at $77.25 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in